lung capacity News
-
FRI: In The transition from Research to Clinical Practice
“Quantitative imaging of the airways, for example with functional respiratory imaging (FRI), is evolving from a research tool towards clinical applications” ,Dr. Maarten van den Berge, thoracic physician at the University of Groningen, states in a recently published interview. “For the past 15 years, FEV1 measurements have been the gold standard and are included in the GOLD ...
By Fluidda
-
IAQ Marketing Specialist Reveals his Personal Fight with Mold
A fungal infection caused by Coccidioides immitis, also known as Valley Fever, took its toll on Paul Cochrane, President of Cochrane & Associates, LLC. In the October 2010 issue of Indoor Environment Connections a personal story of one of the industry’s own is detailed in an article entitled, “A Fungal Infection of the Lungs”. The article details the story of the ...
-
Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics
Albuquerque. NM, Nob Hill Therapeutics announced today the appointment of Craig Davies-Cutting, PhD, as Vice President of Research and Development. Dr. Davies-Cutting will contribute his extensive respiratory product development and industry expertise to the development and commercialization of Nob Hill Therapeutics’ first-of-its-kind DryNeb dry powder nebulizer inhalation drug delivery ...
-
Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO
ALBUQUERQUE, N.M. (PRWEB) August 23, 2022 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug ...
-
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
-
Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...
-
FRI - Understanding The Link Between Pulmonary Vasculature Abnormalities and DCLO in Covid-19
In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial link between DLCO and Pulmonary Vascular Abnormalities in COVID19. COVID-19 is a respiratory viral illness causing pneumonia and systemic disease. Abnormalities in pulmonary function tests infection have been described. The determinants of these ...
By Fluidda
-
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). ...
-
NDD’s new inline filters offer additional protection against COVID-19 during lung function tests
NDD Medical Technologies (NDD), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has introduced new single patient-use, inline filters for its lung function testing devices, in response to the global COVID-19 pandemic. Ensuring an added level of safety, the new filters can be used with NDD’s ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you